Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLK4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLK4 Active Kinase / Mutant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for kinase assays. |
View PLK4 Products |
| Gene Delivery | PLK4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to monitor centriole duplication. |
View PLK4 Products |
| Benchmark Ab | Anti-PLK4 Recombinant Antibody Recombinant positive control for western blot and immunofluorescence. |
View PLK4 Products |
| Validator | PLK4 siRNA Set For knockdown verification and functional validation. |
View PLK4 Products |
| Related Target A | AURKA Synergistic mitotic kinase; co-targeting often evaluated in genomic instability models. |
View AURKA Products |
| Related Target B | TP53 Synthetic lethality partner; PLK4 inhibitors show enhanced efficacy in TP53-deficient tumors. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Off-target Kinase Profiling (PLK1/2/3) | High-purity PLK family recombinant proteins (PLK1, PLK2, PLK3) available for cross-reactivity and selectivity panels. |
| Acquired Resistance Screening | Custom mutant recombinant kinase domains designed based on clinical resistance profiles, sequence verified. |
| Lack of Controls | Clinical benchmark antibodies and verified reference sequences included |
| False Positives | Validated siRNA sets included for target-specific knockdown verification |
Live PLK4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PLK4 therapeutics is intensifying, with major players shifting focus from broad mitotic inhibitors to highly selective small molecule inhibitors targeting centriole duplication. As first-generation therapies reach the clinic, the next wave of R&D is targeting synthetic lethal interactions (such as in TP53-deficient or TRIM37-amplified breast cancers) and overcoming acquired gatekeeper mutations in the PLK4 kinase domain.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Treadwell Therapeutics, Boston Oncology | Solid Tumors, Triple-Negative Breast Cancer (TNBC) | Selectivity Assay (Need High-Purity PLK1/2/3/4 Kinase Panel) |
| Synthetic Lethal Combinations | Academic Institutions, Biotech Startups | TP53-Mutant Tumors, TRIM37-Amplified Cancers | Stable Cell Lines (Need Lentivirus Premade Particles for Target Overexpression) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Advanced Refractory Malignancies | Ubiquitination & Binding Assays (Need Biotinylated PLK4 & Mutants) |